Cascades Says New 2035 GHG Targets Approved by Science Based Targets Initiative
MT newswire2026/10/08 15:4311:43 AM EDT, 10/08/2026 (MT Newswires) -- Cascades (CAS.TO) said on Thursday that its new 2035 greenhouse gas (GHG) emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). Cascades launched its fifth Sustainability Plan in June, committing to cut Scopes 1 and 2 GHG emissions by 67.2% by 2035 and Scope 3 GHG emissions by 41.3%, using 2019 as the base year. "The approval of our new GHG emissions reduction targets by the SBTi is an important recognition of our climate commitment and demonstrates the credibility of our decarbonization roadmap. While these targets are ambitious, they are supported by robust action plans and initiatives that are already well established across our operations. By leveraging innovation, collaboration and disciplined investment management, we are confident in our ability to continue reducing our carbon footprint while creating sustainable value," said Hugues Simon, chief executive officer at Cascades. The SBTI was established through a partnership among the Carbon Disclosure Project (CDP), the United Nations Global Compact, the World Resources Institute (WRI) and the World Wildlife Fund for Nature (WWF). Cascades shares were last seen down CA$0.47 at CA$17.31 on the Toronto Stock Exchange. Price: 17.31, Change: -0.47, Percent Change: -2.64
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
